Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03907475
Title Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

Advanced Solid Tumor

Therapies

Durvalumab

Durvalumab + Nab-paclitaxel

Capecitabine + Durvalumab

Durvalumab + Pegylated liposomal-doxorubicin

Durvalumab + Gemcitabine

Durvalumab + Paclitaxel

Carboplatin + Durvalumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.